Skip to main content
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc. — Investor Relations & Filings

Ticker · ENVB ISIN · US02362F3029 US Professional, scientific and technical activities
Open in API
Filings indexed 1,028 across all filing types
Latest filing 2023-10-31 Regulatory Filings
Country US United States of America
Listing US ENVB

About Enveric Biosciences, Inc.

https://www.enveric.com/

Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. The company focuses on conditions such as anxiety, depression, and addiction. Leveraging its proprietary discovery and development platform, The Psybrary™, Enveric has created a robust intellectual property portfolio of novel molecules for specific mental health indications. Its development pipeline includes candidates such as EB-003 for difficult-to-treat mental health disorders and the EVM301 series.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 31, 2023, which is a current report used to announce unscheduled material events or corporate changes. The content includes a press release about receiving a Notice of Allowance for a patent application, which is attached as an exhibit. The document explicitly states it is a Current Report pursuant to the Securities Exchange Act of 1934 and includes no financial statements or detailed financial data. The length is 4400 characters, which is relatively short and consistent with a current report rather than a full financial report. The document does not fit categories like Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is not a report publication announcement since it contains substantive information about a material event. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2023-10-31 English
Investor Presentation 2023
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Enveric Biosciences, Inc. It primarily announces that the CEO will present at an upcoming investor event and includes a press release and investor presentation as exhibits. The text explicitly states that the investor presentation is furnished as an exhibit and is also available on the company's website. The document does not contain detailed financial statements or substantive financial data but rather serves as a disclosure of an event and related materials. This fits the description of an Investor Presentation (IP) filing type, as it focuses on presenting information to investors about company strategy and events. The document is not an earnings release, annual report, or regulatory filing of financial results, nor is it a report publication announcement since it includes the presentation itself as an exhibit. Therefore, the most appropriate classification is Investor Presentation (IP).
2023-10-20 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 18, 2023, by Enveric Biosciences, Inc. It reports a press release about the initiation of toxicology and safety pharmacology studies for a drug candidate. The document includes standard Form 8-K sections such as Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The content is a current report on a material event, not a full financial report or earnings release. It is a regulatory announcement of a corporate event or update, typical of Form 8-K filings. The document length is 4338 characters, which is relatively short and consistent with a regulatory filing rather than a detailed report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-10-18 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 11, 2023, by Enveric Biosciences, Inc. It includes a Regulation FD Disclosure about a press release announcing a presentation at a conference and references an attached press release as Exhibit 99.1. The document is short (4358 characters) and primarily serves as a current report to disclose a specific event rather than providing detailed financial data or comprehensive reports. It does not contain financial statements or detailed analysis but rather a notification of an event and a press release. According to the rules, such filings that announce or disclose events without substantive financial data or detailed reports are classified as Regulatory Filings (RNS).
2023-10-11 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 3, 2023, by Enveric Biosciences, Inc. It includes a Regulation FD Disclosure about a press release announcing the company's Psybrary portfolio milestone. The document explicitly states it is a Current Report pursuant to the Securities Exchange Act of 1934. There are no detailed financial statements or comprehensive financial data presented; rather, it is a disclosure of a press release event. Form 8-K filings are current reports used to announce major events that shareholders should know about. This fits the category of Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report. The document length is 4303 characters, which is relatively short and consistent with a regulatory announcement rather than a full report.
2023-10-03 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions a press release about the publication of a scientific paper and includes a Regulation FD Disclosure. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is short (4377 characters) and primarily serves as an announcement of a press release publication. According to the rules, such announcements that do not contain substantive financial data or detailed reports should be classified as Regulatory Filings (RNS).
2023-09-27 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.